The independent platform for news, articles and advice for professionals in laboratory medicine

New long COVID research launched

PolyBio Research Foundation has announced the second phase of its Long Covid Research Consortium (LCRC), including the distribution of $15 million to fund research and clinical trials. With its new phase of research, PolyBio expands the consortium's international reach, adding teams based in France, the UK, and Sweden.

Over a dozen institutions globally participate in PolyBio's consortium, including leading scientists from Harvard, University of Pennsylvania, Mount Sinai, Yale, and the University of California San Francisco (UCSF).

In distributing its second round of funds, PolyBio will invest in deepening research on persistence of the SARS-CoV-2 virus in the tissue of long COVID patients, covered in Nature. "Persistence of the virus in the gut is one of the biggest leads in the space," says Dr Sara Cherry, the John W. Eckman Professor of Medical Science in Pathology and Laboratory Medicine at the University of Pennsylvania, whose team is working to identify drug combinations that can eliminate virus in gut tissue.

PolyBio will also fund UCSF to launch the world's first programme to collect comprehensive tissue samples from long COVID patients. "The UCSF team contains people who made HIV/AIDS a treatable disease. These researchers rapidly pivoted into Long COVID at the outset of the pandemic," says PolyBio President Dr Amy Proal.

Pictured above is consortium member and PolyBio Co-Founder Dr Michael VanElzakker of Harvard University analysing platelet blood cells from long COVID patients.

PolyBio's second phase of projects also includes funding for clinical trials evaluating HIV antivirals for long COVID, a top priority of patients. "If HIV antivirals have a positive impact on long COVID, the ability to improve the lives of patients is that much closer at hand, as these drugs are affordable and safety tested," says Dr David Putrino, who serves as the Nash Family Director of Mount Sinai's Cohen Center for Recovery From Complex Chronic Illnesses (CoRE), which will direct the clinical trials.

 

Upcoming Events

Pathology Horizons 2024

MacDonald Bath Spa Hotel, Bath
18-20 April, 2024

Diagnostics North East Conference 2024

The Catalyst, Newcastle upon Tyne
19 April, 2024

ECCMID 2024 - European Congress of Clinical Microbiology and Infectious Diseases

Fira Gran Via, 08038 Barcelona, Spain
27-30 April 2024

British Society for Microbial Technology Annual Microbiology Conference

UK Health Security Agency, Colindale, London
2 May 2024

EQA Reports: Interpreting Key Information & Troubleshooting Tips

ONLINE - Zoom
Thursday 16th May 2024

Participants’ Meeting: UK NEQAS Immunology, Immunochemistry & Allergy

Sheffield Hallam University, City Campus, Howard Street, Sheffield
24th May 2024

Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.

Download the FREE Pathology In Practice app from your device's App store

Upcoming Events

Pathology Horizons 2024

MacDonald Bath Spa Hotel, Bath
18-20 April, 2024

Diagnostics North East Conference 2024

The Catalyst, Newcastle upon Tyne
19 April, 2024

ECCMID 2024 - European Congress of Clinical Microbiology and Infectious Diseases

Fira Gran Via, 08038 Barcelona, Spain
27-30 April 2024

British Society for Microbial Technology Annual Microbiology Conference

UK Health Security Agency, Colindale, London
2 May 2024

EQA Reports: Interpreting Key Information & Troubleshooting Tips

ONLINE - Zoom
Thursday 16th May 2024

Participants’ Meeting: UK NEQAS Immunology, Immunochemistry & Allergy

Sheffield Hallam University, City Campus, Howard Street, Sheffield
24th May 2024

Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.

Download the FREE Pathology In Practice app from your device's App store

Step Communications Ltd, Step House, North Farm Road, Tunbridge Wells, Kent TN2 3DR
Tel: 01892 779999
www.step-communications.com
© 2024 Step Communications Ltd. Registered in England. Registration Number 3893025